ReviewMayo Clinic proceedings. Innovations, quality & outcomes2022
Updates on the Diagnosis and Management of Glaucoma.
Review in Mayo Clinic proceedings. Innovations, quality & outcomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07074782 (Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues), which is not on this map. Cited by 96 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues: NEUROPA - a Retrospective Cohort Study
Who cites it
96 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Prenatal and childhood exposure to smoking and retinal nerve fibre layer thickness: A meta-analysis of three independent birth cohorts.Acta ophthalmologica · 2026Pooled it
- The effect of selective laser trabeculoplasty on the intraocular pressure of the contralateral eye - a systematic review and meta-analysis.Eye (London, England) · 2026Pooled it
- Paul tube implant: a meta-analysis and systematic review evaluating clinical outcomes.Eye (London, England) · 2026Pooled it
- Physical activity and exercise in primary open-angle glaucoma: a scoping review.Frontiers in physiology · 2026Pooled it
- Identifying potential key metabolic pathways and biomarkers in glaucoma: a systematic review and meta-analysis.BMJ open ophthalmology · 2025Pooled it
- Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study.The British journal of ophthalmology · 2026Trial
- Exome-wide screening discovers novel pathogenic variants in Vietnamese primary congenital glaucoma patients.Genes & genomics · 2026Article
- PEBP1 Regulates Ferroptosis in Acute Glaucoma: Targeted Therapy Using Engineered Exosomes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Natural history of glaucoma suspects in a tertiary eye centre in Singapore.Eye (London, England) · 2026Article
- Pharmacological assessment of drugs retained in the 1Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Extrinsic Regulation of Optic Nerve Axon Regeneration in the Adult Central Nervous System.Cells · 2026Review
- Latanoprost Acid-Brimonidine, a New Amide Prodrug for Glaucoma Management Based on the Concept of Sustained Release.Molecules (Basel, Switzerland) · 2026Article
- Neurotoxic effects of dietary glutamate in glaucoma and potential nutritional and pharmacological therapies: a scoping review.International ophthalmology · 2026Article
- Ferroptosis regulator NOX1 acts a diagnostic biomarker and mediates disease progression with the transcriptional regulation of STAT3 in glaucoma.Indian journal of ophthalmology · 2026Article
- Understanding Patient Preferences and Their Impact on Adherence to Glaucoma Therapy: A Multicenter Cross-Sectional Study.Ophthalmology and therapy · 2026Article
- Primary Open-Angle Glaucoma among Black and Latinx Populations: Exploring Racial Disparities in the United States.Journal of racial and ethnic health disparities · 2026Review
- Primary Open-Angle Glaucoma With Improved Visual Outcomes Following Audio-Luminous Biofeedback Training: A Case Report.The American journal of case reports · 2026Article
- Analysis of Histostructural Modifications in the Ocular Surface of Patients With Chronic Glaucoma.Investigative ophthalmology & visual science · 2026Article
- Outcomes of Micropulse Transscleral Cyclophotocoagulation in Primary Open-Angle and Pseudoexfoliative Glaucoma.Medicina (Kaunas, Lithuania) · 2026Article
- Hypertensive phase after a novel small-lumen non-valved drainage device: predictive factors and two-year outcomes.Japanese journal of ophthalmology · 2026Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is the leading cause of blindness throughout the world (after cataracts); therefore, general physicians should be familiar with the diagnosis and management of affected patients. Glaucomas are usually categorized by the anatomy of the anterior chamber angle (open vs narrow/closed), rapidity of onset (acute vs chronic), and major etiology (primary vs secondary). Most glaucomas are primary (ie, without a contributing comorbidity); however, several coexisting ophthalmic conditions may serve as the underlying etiologies of secondary glaucomas. Chronic glaucoma occurs most commonly; thus, regular eye examinations should be performed in at-risk patients to prevent the insidious loss of vision that can develop before diagnosis. Glaucoma damages the optic nerve and retinal nerve fiber layer, leading to peripheral and central visual field defects. Elevated intraocular pressure (IOP), a crucial determinant of disease progression, remains the only modifiable risk factor; thus, all current treatments (medications, lasers, and operations) aim to reduce the IOP. Pharmacotherapy is the usual first-line therapy, but noncompliance, undesirable adverse effects, and cost limit effectiveness. Laser and surgical treatments may lower IOP significantly over long periods and may be more cost effective than pharmacotherapy, but they are plagued by greater procedural risks and frequent treatment failures. Traditional incisional procedures have recently been replaced by several novel, minimally invasive glaucoma surgeries with improved safety profiles and only minimal decreases in efficacy. Minimally invasive glaucoma surgeries have dramatically transformed the surgical management of glaucoma; nevertheless, large, randomized trials are required to assess their long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.